Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Coherus Oncology Inc (CHRS)

154 + Investors. Track Smart Money conviction in CHRS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +28
Streak
3Q ▲
Buyers last Q
63%

Smart Money Signals — CHRS

Based on 155 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added CHRS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (96% of max)

96% of all-time peak
155 hedge funds hold CHRS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +34% more funds vs a year ago

fund count last 6Q
+39 new funds entered over the past year (+34% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 63% buying

89 buying52 selling
Last quarter: 89 funds were net buyers (42 opened a brand new position + 47 added to an existing one). Only 52 were sellers (38 trimmed + 14 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+14 vs last Q)

new funds entering per quarter
Funds opening a new CHRS position: 13 → 22 → 28 → 42. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 24% medium ■ 25% new
80 out of 155 hedge funds have held CHRS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +32% but shares only +16% — price-driven

Value
+32%
Shares
+16%
Last quarter: the total dollar value of institutional holdings rose +32%, but actual share count only changed +16%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

13 → 13 → 22 → 28 → 42 new funds/Q
New funds entering each quarter: 13 → 22 → 28 → 42. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 58% veterans vs 28% newcomers

■ 58% veterans ■ 14% 1-2yr ■ 28% new
Entry-cohort mix of 159 holders: 93 (58%) are 2+ year veterans, 22 entered 1–2 years ago, and 44 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 23% AUM from major funds

23% from top-100 AUM funds
38 of 155 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CHRS

In 2026 Q1, 89 hedge funds were net buyers of CHRS (42 opened a new position, 47 added to an existing one), while 52 reduced or exited (38 trimmed, 14 sold completely) — a 63% buyer ratio, indicating clear institutional accumulation. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 23% of total institutional value in CHRS is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +28 funds (more new holders than closures). Total institutional holders: 155.

Hedge Fund Ownership: CHRS

How many hedge funds hold CHRS — quarterly history vs. share price
Quarterly hedge fund ownership of CHRS vs. share price

Market Analysis: CHRS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CHRS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Coherus Oncology Inc (CHRS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CHRS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
CHRS
-17.5%
XLV
+4.0%

CHRS outperformed XLV by -21.5% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
CHRS
-11.1%
XLV
+5.1%

Since the filing became public, CHRS outperformed XLV by -16.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

16 top-rated funds 1 high-conviction
Consensus
5.3
/ 10
breadth
×
Elite
2.0
/ 10
conviction
Hedge Fund Positioning: CHRS
154 + Investors

Track Smart Money conviction in CHRS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 154 127 21.26%
13F Shares 60M 51M 16.04%
Total Value $96M $73M 32.11%
New Positions 41 28 +13
Increased Positions 47 37 +10
Closed Positions 14 13 +1
Reduced Positions 36 35 +1
Total Calls 2 2 -
Total Puts 2 1 100.0%
PUT/CALL Ratio 1.0 0.5 Neutral

Statistics: CHRS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

154 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CHRS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CHRS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 CM Management, LLC 2.97% 2,100,000 $3.5M
2 Propel Bio Management, LLC 1.52% 1,420,550 $2.4M
3 Samsara BioCapital, LLC 0.56% 3,428,571 $5.8M
4 Tang Capital Management LLC 0.16% 1,886,748 $3.2M
5 Pvg Asset Management Corp 0.11% 133,360 $181K
6 Kohlberg Kravis Roberts & Co. L.P. 0.09% 3,036,076 $5.1M
7 Dauntless Investment Group, LLC 0.09% 76,087 $129K
8 Tyche Wealth Partners LLC 0.06% 240,868 $407K
9 Informed Momentum Co LLC 0.06% 309,801 $524K
10 Headlands Technologies LLC 0.02% 100,272 $169K
11 Providence Wealth Advisors, LLC 0.02% 15,000 $26K
12 Carr Financial Group Corp 0.02% 35,195 $59K
13 Bridgeway Capital Management, LLC 0.01% 441,000 $745K
14 Shay Capital LLC 0.01% 105,326 $178K
15 Alyeska Investment Group, L.P. 0.01% 2,250,000 $3.8M
16 Hudson Bay Capital Management LP 0.01% 1,704,980 $2.9M
17 Panagora Asset Management Inc 0.01% 1,459,310 $2.5M
18 Endowment Wealth Management, Inc. 0.01% 11,521 $19K
19 Simplify Asset Management Inc. 0.01% 253,140 $428K
20 NINE MASTS CAPITAL Ltd 0.01% 23,018 $39K
21 International Assets Investment Management, LLC 0.01% 42,408 $74K
22 SteelPeak Wealth, LLC 0.00% 69,000 $117K
23 China Universal Asset Management Co., Ltd. 0.00% 26,525 $45K
24 Bronte Capital Management Pty Ltd. 0.00% 19,282 $33K
25 Two Sigma Investments, LP 0.00% 2,302,001 $3.9M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Coherus Oncology Inc (CHRS)

What does the Smart Money Trend signal show for CHRS?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added CHRS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CHRS?

More buyers than sellers — 63% buying: Last quarter: 89 funds were net buyers (42 opened a brand new position + 47 added to an existing one). Only 52 were sellers (38 trimmed + 14 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CHRS holders?

Strong quality — 23% AUM from major funds: 38 of 155 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CHRS?

52% of holders stayed for 2+ years: 80 out of 155 hedge funds have held CHRS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Coherus Oncology Inc (CHRS) following the 2026 Q1 hedge fund 13F filings?

As of today, CHRS has moved -11.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.1% for the XLV sector ETF — an outperformance of -16.2%. Since the quarter end (March 31, 2026), CHRS has gained -17.5% vs +4.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →